Boston Scientific Receives FDA Approval for Lotus Edge TAVR System


April 23, 2019—Boston Scientific Corporation announced that it has received FDA approval for its Lotus Edge aortic valve system for transcatheter aortic valve replacement (TAVR). The device is approved for patients with severe aortic stenosis who are considered at high risk for surgical valve replacement.

According to the company, the Lotus Edge system gives physicians the option to reposition and completely recapture the valve once it has been fully deployed. It also features a braided valve frame and an adaptive seal that minimizes paravalvular regurgitation or leaking by conforming to the patient’s native aortic valve.

In March, the company commenced a controlled launch of the Lotus Edge valve system in Europe. A controlled launch in the United States is expected to begin in the coming weeks, advised Boston Scientific.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.